How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Tumor Models Market
- By Model Type: In Vivo Tumor Models, In Vitro Tumor Models, Ex Vivo Tumor Models, 3D Tumor Spheroid Models, Patient-Derived Xenograft (PDX) Models
- By Tumor Origin: Human Tumor Models, Murine Tumor Models, Canine Tumor Models, Rat Tumor Models, Zebrafish Tumor Models
- By Tumor Type: Breast Cancer Models, Lung Cancer Models, Colorectal Cancer Models, Prostate Cancer Models, Melanoma Models, Glioblastoma Models
- By Application: Drug Discovery and Development, Cancer Biology Research, Immuno-oncology Studies, Toxicology Testing, Biomarker Identification
- By Model Development Technique: Genetically Engineered Models, Chemically Induced Models, Orthotopic Tumor Models, Subcutaneous Tumor Models, Syngeneic Tumor Models
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - In Vivo Tumor Models leads By Model Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 308 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.187 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.195 →
Full report · locked preview
Everything inside the Tumor Models Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Model Type 5
Tumor Origin 5
Tumor Type 6
Application 5
Model Development Technique 5
Companies profiled
Charles River Laboratories International Inc.
Envigo (a part of Inotiv)
Taconic Biosciences Inc.
The Jackson Laboratory
Crown Bioscience Inc.
Biocytogen Co. Ltd.
SAGE Labs (a division of BioIVT)
BioreclamationIVT
Harlan Laboratories (now part of Envigo)
WuXi AppTec
PhenoVista Biosciences
Oncodesign
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Envigo (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Taconic Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →The Jackson Laboratory
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Crown Bioscience Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Biocytogen Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →SAGE Labs (a division of BioIVT)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →BioreclamationIVT
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Harlan Laboratories (now part of Envigo)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →WuXi AppTec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →PhenoVista Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Oncodesign
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →GenScript Biotech Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cyagen Biosciences Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Innovative Targeting Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,350M by 2033 · 5.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- In Vivo Tumor Models42.5
- In Vitro Tumor Models18.9
- Ex Vivo Tumor Models9.1
- 3D Tumor Spheroid Models17.6
- Patient-Derived Xenograft (PDX) Models11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,343M → $1,914M · 4.5%
Europe$935.8M → $1,509M · 6.2%
Asia Pacific$854.4M → $1,192M · 4.3%
Latin America$528.9M → $758.1M · 4.6%
Middle East and Africa$406.8M → $676.1M · 6.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.672026
5.692027
5.692028
5.712029
5.732030
5.742031
5.752032
5.772033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.12.0
- Envigo (a part of Inotiv)14.9
- Taconic Biosciences Inc.13.8
- The Jackson Laboratory8.0
- Crown Bioscience Inc.12.0
- Biocytogen Co. Ltd.11.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Model Type27.7%
Tumor Origin19.3%
Tumor Type11.3%
Application15.8%
Model Development Technique25.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe24.9
- Asia Pacific19.7
- Latin America12.5
- Middle East and Africa11.2
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 78 | 94 | 91 | 96 | 84 | 76 | 87 |
| Envigo (a part of Inotiv) | 82 | 68 | 88 | 84 | 80 | 89 | 82 |
| Taconic Biosciences Inc. | 74 | 81 | 72 | 71 | 87 | 77 | 77 |
| The Jackson Laboratory | 58 | 58 | 57 | 77 | 75 | 65 | 65 |
| Crown Bioscience Inc. | 76 | 61 | 77 | 62 | 56 | 63 | 66 |
| Biocytogen Co. Ltd. | 61 | 57 | 53 | 54 | 65 | 54 | 57 |
| SAGE Labs (a division of BioIVT) | 48 | 63 | 55 | 55 | 46 | 42 | 52 |
| BioreclamationIVT | 42 | 51 | 41 | 42 | 44 | 59 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Envigo (a part of Inotiv)
- Taconic Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Envigo (a part of Inotiv) | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Taconic Biosciences Inc. | ✓ | ◐ | − | ◐ | ✓ | ◐ |
| The Jackson Laboratory | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Crown Bioscience Inc. | ◐ | − | ✓ | − | − | ◐ |
| Biocytogen Co. Ltd. | ◐ | ◐ | − | − | − | − |
| SAGE Labs (a division of BioIVT) | − | − | − | ◐ | − | ◐ |
| BioreclamationIVT | ◐ | − | ◐ | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.87
2Envigo (a part of Inotiv)82
3Taconic Biosciences Inc.77
4Crown Bioscience Inc.66
5The Jackson Laboratory65
6Biocytogen Co. Ltd.57
7SAGE Labs (a division of BioIVT)52
8BioreclamationIVT47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Envigo (a part of Inotiv)
Challenger1
Strong scale, closing on the leaders.
Taconic Biosciences Inc.
Contender3
Focused players with pockets of strength.
The Jackson LaboratoryCrown Bioscience Inc.Biocytogen Co. Ltd.
Niche2
Specialists in a single segment or region.
SAGE Labs (a division of BioIVT)BioreclamationIVT
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Model Type in North America, then scale across Tumor Models Market — a $115M beachhead inside a $1.74B market.
Beachhead (SOM)$115Mobtainable near-term
Serviceable (SAM)$706Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
In Vivo Tumor Models
Best fit — highest urgency & budget in Model Type.
Economic buyer77 fit
In Vitro Tumor Models
Strong fit — clear ROI and a fast path to value.
End user68 fit
Ex Vivo Tumor Models
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Model Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Tumor Origin & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Tumor Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Model Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Tumor Models Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation14%
Closed-won5%
$12.9KCAC
$64KLTV
5.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Tumor Models Market is a durable-growth opportunity — $7.11B by 2033, compounding at 6.9%.
TAM · 2025$4.18Btoday
TAM · 2033$7.11Bforecast
CAGR6.9%2027–2033
Cumulative$49.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.11BTotal addressable market
SAM$2.68BServiceable available market
SOM$524MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.9% CAGR
Demand compounds through 2033, outpacing GDP across Model Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Model Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.11BLarge & growingTAM by 2033 at 6.9% CAGR
$2.68BServiceable nowreachable with today’s model
$524MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.55BBear4.5% CAGR
$7.11BBase6.9% CAGR
$9.10BBull9.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Tumor Origin optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Tumor Models Market — a $1.09B market by 2033. Plan: grow share from 9.4% to 17.9%.
Market size · 2033$1.09Btotal addressable
Market CAGR7.9%2027–2033
Target share17.9%from 9.4% today
Revenue ambition$196Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.4% | 17.9% | At risk |
| Revenue | $98M | $196M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.5% | 44.0% | Ahead |
| Customer retention | 84.5% | 94.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Model Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Tumor Origin capability
A defensible second engine — invest in Tumor Origin to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Model Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Tumor Origin
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $20M capacity & capability investment
- Greenlight bolt-on M&A in Tumor Origin
- Authorise North America expansion plan
- Fund R&D program for Model Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Tumor Models Market conversation — a $5.40B market you can size, segment and defend in minutes.
Market size · 2033$5.40Btotal opportunity
Growth3.6%CAGR to 2033
Addressable buyers1,333+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Model Type
Goal Grow share in Model Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 4 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Envigo (a part of Inotiv)Taconic Biosciences Inc.The Jackson LaboratoryCrown Bioscience Inc.Biocytogen Co. Ltd.SAGE Labs (a division of BioIVT)BioreclamationIVT+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Tumor Models Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Tumor Models Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Tumor Microwave Ablation Devices Market
Market size, share, segmentation and regional forecast.
$316M market · 2025 base year
View reportTumor Mice Model Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportTumor Marker Test Kits Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportTumor Markers Immunoassay Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportTumor Markers for Primary Liver Cancer Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportTumor Markers Detection Kit Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportTumor Marker Detection Products Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportTumor Marker Detection Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportTumor Lysis Syndrome Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportTumor Localization System Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportTumor Infiltrating Lymphocyte (TIL) Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportTumor Immunotherapy Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.